Oakwood Labs

Oakwood offers end-to-end solutions supporting all phases of long-acting injectable (LAI) development using its in-house Chroniject technology, which enables tunable release profiles from 1 week up to 1 year and has been used to encapsulate a variety of molecule types. As an experienced CDMO partner, the company offers expertise from feasibility assessment through scale-up, technology transfer, and aseptic manufacturing of clinical and commercial supply, along with full analytical method development and stability services.